Cyclo Therapeutics Inc expected to post a loss of 16 cents a share - Earnings Preview

Cyclo Therapeutics

14/03/2025 11:42

Cyclo Therapeutics Inc CYTH.OQ CYTH.O is expected to show a rise in quarterly revenue when it reports  results on March 17 (estimated) for the period ending December 31 2024

The Gainesville Florida Florida-based  company is expected to report a 3.5% increase in revenue to $322 thousand from $311 thousand a year ago, according to the mean estimate from 3 analysts, based on LSEG data.

‚ÄčLSEG's mean analyst estimate for Cyclo Therapeutics Inc is for a loss of 16 cents per share.

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ‚Äč

Wall Street's median 12-month price target for Cyclo Therapeutics Inc is $0.95‚Äč, above‚Äč its last closing price of $0.70. ‚Äč‚Äč‚Äč

Previous quarterly performance (using preferred earnings measure in US dollars). ‚Äč

QUARTER ENDING
STARMINESMARTESTIMATE¬ģ
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Sep. 30 2024
-0.16
-0.16
-0.27
Missed
-72.3
Jun. 30 2024
-0.15
-0.15
-0.21
Missed
-35.5
Mar. 31 2024
-0.20
-0.20
-0.15
Beat
26.8‚Äč
-0.34
‚Äč‚Äč
-0.29
Jun. 30 2023
-0.44
-0.33
Beat
25‚Äč
Mar. 31 2023
-0.42
-0.42
-0.46
Missed
-9.5
Dec. 31 2022
-0.25
-0.59
Missed
-136

This summary was machine generated March 14 at 11:42 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)